Return to search

CONTRALATERAL BREAST CANCER IN WOMEN WITH EARLY STAGE BREAST CANCER

Background:
There is uncertainty about the lifetime risk of contralateral breast cancer (CBC) in a woman who is diagnosed with early stage breast cancer. Studies report a wide range of rates of CBC between 2% and 35%.

Objectives:
(i) To determine the risk of CBC in women with early stage breast cancer, and (ii) to evaluate the risk of CBC in women who undergo adjuvant systemic treatment and adjuvant radiation treatment.

Methods:
PubMed, Ovid MEDLINE, EMBASE, Healthstar, Cochrane Central Register for Controlled Trials were searched. Studies were included if participants had: unilateral invasive breast carcinoma; 5 years of median follow-up; a minimum of 100 participants. Randomized controlled trials were included for the meta-analysis. A random-effects meta-analysis was used to estimate the pooled rate of CBC.

Results:
4571 articles were extracted out of which 22 randomized controlled trials were included in the final meta-analysis. The overall pooled rate of CBC was 0.36% per year, (95% CI, 0.32% - 0.41%). The rate of CBC in studies without adjuvant systemic treatment was higher than the rate without such treatment, 0.56% per year (95% CI, 0.40% to 0.77%) versus 0.35% per year (95% CI, 0.31% to 0.40%). The rate of CBC in studies with adjuvant radiation treatment was 0.26% per year (95% CI, 0.18% to 0.39%) which is similar to the rate in studies with radiation.

Conclusions:
The rate of CBC in women with early stage breast cancer is relatively low. This is important for breast cancer patients who are considering contralateral prophylactic mastectomy. / Thesis / Master of Science (MS) / The rate of contralateral breast cancer in women with early stage breast cancer is uncertain. In order to determine this rate, a systematic review and meta analysis was conducted. The rate of contralateral breast cancer in women with early stage breast cancer was found to be 0.36% per year. This rate appears to be constant for up to 10 years after the original breast cancer diagnosis. This data is important for women with breast cancer and their healthcare teams in order to make decisions about bilateral mastectomy.

Identiferoai:union.ndltd.org:mcmaster.ca/oai:macsphere.mcmaster.ca:11375/18515
Date January 2015
CreatorsRana, Punam
ContributorsLevine, Mark, Health Research Methodology
Source SetsMcMaster University
LanguageEnglish
Detected LanguageEnglish
TypeThesis

Page generated in 0.002 seconds